We have all grown up with the idea that if a woman suspects she is pregnant she can simply pop into a pharmacy and buy a pregnancy test to use at home.
Conversely, if someone suspects they are suffering from heart disease, cancer, or an infection their first instinct is to contact a GP or call an ambulance.
So the obvious question is why easy-to-use self-tests have not yet been developed for life-threatening diseases.
The answer is straightforward for a scientist: it is to do with the level of the biomarker - in this case, the proteins produced by the cells in the body that are specific to the particular condition - that must be measured.
Not only that but one has to measure the complexity of the biological sample - the blood or serum in the case of biomarkers. The impact of those two aspects is huge, as revealed by the very limited technological alternatives to "dipstick" tests currently available to the global healthcare market.
The "pregnancy test" is actually a great example of a dipstick test capable of detecting the presence of a pregnancy hormone called human chronic gonadotrophin (hCG) in urine, which is produced by the body after conceiving.
The test uses similar chemistry to the one involved in measuring many other protein biomarkers from blood - but the measurement of protein biomarkers remains limited to bulky clinical pathology labs and companies are still struggling to miniaturise this sophisticated lab equipment.
Clinical diagnostics influences about 70% of healthcare decisions, which means they are the foundation of a cost-effective healthcare system.
Diagnostic tests provide critical physiological or biochemical information that physicians or patients need for the best healthcare decisions.
So in an era when most humans struggle to live without portable computers, tablets, smartphones and the rest - why has a "personal lab" not yet been invented?
Mobile computers only became possible because of major breakthroughs in battery life, transistors, integrated circuits and software development, which allowed incredible levels of miniaturisation. Clinical lab equipment needs to undergo a similar revolution to the one that led to the development of modern computers.
Small is beautiful
But our research group has recently demonstrated a miniaturised concept for rapid and accurate diagnosis of certain health conditions, such as myocardial infarction, sepsis and different types of cancer.
The unique optical transparency of this micro-engineered material allows us to overcome the traditional barriers to signal interception - one of the most difficult components to miniaturise in a clinical pathology system - by using off-the-shelf parts.
Due to the simplicity of the technology, the tests can be performed in local medical centres - or even in patient's houses - improving health treatments and reducing patient anxiety.
The MCF is an ultra low-cost flat transparent film with a number of embedded microcapillaries. Each capillary works as a miniature reaction chamber where the blood sample is inserted and tested.
After a certain reaction time, which can be 15 minutes for prostate cancer or slightly longer for myocardial infarction and sepsis, the capillaries exhibit a signal that can be detected by a smartphone or a simple flatbed scanner.
This signal can be related to certain amounts of a protein biomarker that is directly correlated with a certain health condition allowing its early detection and treatment. MCF technology provides low-cost, rapid and accurate measurement of protein biomarkers for point-of-care diagnostics, improving the speed and quality of health care decisions and patient treatments.
So let's get our scientific and engineering minds together and revolutionise clinical diagnostics with personal labs accessible to all.